03692 PE Ratio & Valuation, Is 03692 Overvalued

Historical Valuation

HANSOH PHARMA (03692) is now in the Fair zone, suggesting that its current forward PE ratio of 38.98 is considered Fairly compared with the five-year average of 29.77. The fair price of HANSOH PHARMA (03692) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：33.64

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is HANSOH PHARMA (03692) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

HANSOH PHARMA (03692) has a current Price-to-Book (P/B) ratio of 6.54. Compared to its 3-year average P/B ratio of 5.98, the current P/B ratio is approximately 9.30% higher. Relative to its 5-year average P/B ratio of 5.98, the current P/B ratio is about 9.30% higher. HANSOH PHARMA (03692) has a Forward Free Cash Flow (FCF) yield of approximately 2.27%. Compared to its 3-year average FCF yield of 2.00%, the current FCF yield is approximately 13.58% lower. Relative to its 5-year average FCF yield of 2.00%, the current FCF yield is about 13.58% lower.

Performance Decomposition

AI Analysis

Market capitalization of 03692 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 03692 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 03692 currently overvalued or undervalued?

What is HANSOH PHARMA (03692) fair value?

03692's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of HANSOH PHARMA (03692) is between to according to relative valuation method.

How does 03692's valuation metrics compare to the industry average?

The average P/S ratio for 03692's competitors is 0.00, providing a benchmark for relative valuation. HANSOH PHARMA Corp (03692) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for HANSOH PHARMA (03692) as of Mar 11 2026?

As of Mar 11 2026, HANSOH PHARMA (03692) has a P/B ratio of 6.54. This indicates that the market values 03692 at 6.54 times its book value.

What is the current FCF Yield for HANSOH PHARMA (03692) as of Mar 11 2026?

As of Mar 11 2026, HANSOH PHARMA (03692) has a FCF Yield of 2.27%. This means that for every dollar of HANSOH PHARMA's market capitalization, the company generates 2.27 cents in free cash flow.

What is the current Forward P/E ratio for HANSOH PHARMA (03692) as of Mar 11 2026?

As of Mar 11 2026, HANSOH PHARMA (03692) has a Forward P/E ratio of 38.98. This means the market is willing to pay $38.98 for every dollar of HANSOH PHARMA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for HANSOH PHARMA (03692) as of Mar 11 2026?

As of Mar 11 2026, HANSOH PHARMA (03692) has a Forward P/S ratio of 12.92. This means the market is valuing 03692 at $12.92 for every dollar of expected revenue over the next 12 months.

03692 Valuation